ES2177295T3 - Parche transdermal tipo matriz para hormonas esteroides. - Google Patents
Parche transdermal tipo matriz para hormonas esteroides.Info
- Publication number
- ES2177295T3 ES2177295T3 ES99931130T ES99931130T ES2177295T3 ES 2177295 T3 ES2177295 T3 ES 2177295T3 ES 99931130 T ES99931130 T ES 99931130T ES 99931130 T ES99931130 T ES 99931130T ES 2177295 T3 ES2177295 T3 ES 2177295T3
- Authority
- ES
- Spain
- Prior art keywords
- transdermal patch
- matrix
- matrix type
- steroid hormones
- type transdermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011159 matrix material Substances 0.000 title abstract 5
- 239000003270 steroid hormone Substances 0.000 title 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229960005309 estradiol Drugs 0.000 abstract 2
- 229930182833 estradiol Natural products 0.000 abstract 2
- 239000000583 progesterone congener Substances 0.000 abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Un parche transdermal para la liberación de estradiol y al menos un agente progestógeno a través de la piel, que comprende o consiste en una lámina de respaldo exterior, una matriz y un forro protector, en donde a) el estradiol y el agente o agentes progestógenos están presentes en la matriz en una solución sobresaturada, b) la matriz contiene 1 a 4 % en peso de SiO2 activado y c) la matriz tiene un contenido de humedad de menos de 0, 7 % en peso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19827732A DE19827732A1 (de) | 1998-06-22 | 1998-06-22 | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2177295T3 true ES2177295T3 (es) | 2002-12-01 |
Family
ID=7871628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99931130T Expired - Lifetime ES2177295T3 (es) | 1998-06-22 | 1999-06-22 | Parche transdermal tipo matriz para hormonas esteroides. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6440454B1 (es) |
| EP (1) | EP1089722B1 (es) |
| JP (1) | JP2002518434A (es) |
| KR (1) | KR20010053072A (es) |
| CN (1) | CN1306421A (es) |
| AT (1) | ATE217793T1 (es) |
| AU (1) | AU4775499A (es) |
| BR (1) | BR9911411A (es) |
| CA (1) | CA2333586A1 (es) |
| DE (2) | DE19827732A1 (es) |
| DK (1) | DK1089722T3 (es) |
| ES (1) | ES2177295T3 (es) |
| HU (1) | HUP0102785A2 (es) |
| IL (1) | IL140335A0 (es) |
| PL (1) | PL345061A1 (es) |
| PT (1) | PT1089722E (es) |
| WO (1) | WO1999066908A1 (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064149A1 (en) * | 2000-02-29 | 2001-09-07 | Jie Zhang | Improved transdermal drug patch |
| DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| CA2418135C (en) | 2000-08-03 | 2011-09-20 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| US20040062794A1 (en) * | 2002-09-30 | 2004-04-01 | Lee Shulman | 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy |
| US20040086551A1 (en) | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| NZ541807A (en) | 2003-02-21 | 2009-07-31 | Bayer Schering Pharma Ag | UV stable transdermal therapeutic plaster |
| CA2538856C (en) * | 2003-10-10 | 2010-06-29 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US8668925B2 (en) | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| GB0409498D0 (en) * | 2004-04-28 | 2004-06-02 | Hunter Fleming Ltd | Transdermal steroid formulation |
| US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| US8962013B2 (en) | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| US20070134310A1 (en) * | 2005-09-23 | 2007-06-14 | Nedberge Diane E | Transdermal risperidone delivery system |
| ATE509969T1 (de) * | 2005-09-23 | 2011-06-15 | Nat Starch Chem Invest | Klebstoffe auf acrylpolymerbasis |
| WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
| US20080152592A1 (en) * | 2006-12-21 | 2008-06-26 | Bayer Healthcare Llc | Method of therapeutic drug monitoring |
| US20080226698A1 (en) | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
| WO2008115224A2 (en) * | 2007-03-20 | 2008-09-25 | Bayer Healthcare Llc | Method of analyzing an analyte |
| CA2739380C (en) * | 2008-10-06 | 2014-12-09 | Mylan Technologies, Inc. | Amorphous rotigotine transdermal system |
| AU2015203180B2 (en) * | 2010-09-06 | 2016-06-30 | Bayer Intellectual Property Gmbh | Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) |
| DE102010040299A1 (de) * | 2010-09-06 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner) |
| WO2012031999A2 (en) | 2010-09-06 | 2012-03-15 | Bayer Pharma Aktiengesellschaft | Low-dose transdermal patches with high drug release |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| AU2013264896A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| KR20170040209A (ko) | 2014-07-29 | 2017-04-12 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 경피 크림 |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| ES2799309T3 (es) | 2014-09-29 | 2020-12-16 | Cellix Bio Private Ltd | Compuestos y composiciones para el tratamiento de esclerosis múltiple |
| CA2965449C (en) | 2014-10-27 | 2020-11-10 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| WO2016067297A1 (en) | 2014-10-27 | 2016-05-06 | Cellix Bio Private Limited | Salts of valproic acid with piperazine, ethylenediamine, lysine and/or eicosapentaenoic ecid (epa) amine derivatives for the treatment of epilepsy |
| CN107207411A (zh) | 2014-12-01 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
| CN108451578B (zh) * | 2015-01-09 | 2022-05-24 | 金珂生物医疗公司 | 敷料组件及其使用方法 |
| CA2976187A1 (en) | 2015-02-09 | 2016-08-18 | Cellix Bio Private Limited | Benzydamine salts and compositions thereof useful for the treatment of mucositis |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2018029545A1 (en) | 2016-08-11 | 2018-02-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of irritable bowel syndrome |
| IL265791B (en) | 2016-10-04 | 2022-07-01 | Cellix Bio Private Ltd | Compositions and methods for the treatment of xerostomia |
| EP3554494A4 (en) | 2016-12-19 | 2021-02-17 | Cellixbio Private Limited | INFLAMMATION TREATMENT COMPOSITIONS AND METHODS |
| JP2020528900A (ja) | 2017-07-27 | 2020-10-01 | アラーガン、インコーポレイテッドAllergan,Incorporated | 体脂肪低減のためのプロスタサイクリン受容体アゴニスト |
| EP3709982A4 (en) | 2017-11-17 | 2021-10-13 | Cellix Bio Private Limited | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISEASES AND SKIN DISEASES |
| BR112020009361A2 (pt) | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| US20230125585A1 (en) | 2019-08-02 | 2023-04-27 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559222A (en) * | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
| US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| CA2065311C (en) * | 1989-09-08 | 2000-01-11 | Chia-Ming Chiang | Solid matrix system for transdermal drug delivery |
| DE4210711A1 (de) * | 1991-10-31 | 1993-05-06 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | Transdermale therapeutische systeme mit kristallisationsinhibitoren |
| US5676968A (en) * | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
| DE4223360C1 (es) * | 1992-07-16 | 1993-04-08 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| DE4237453C1 (es) * | 1992-11-06 | 1993-08-19 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| DE4333595A1 (de) * | 1993-10-01 | 1995-04-06 | Labtec Gmbh | Transdermales therapeutisches System zur Applikation von Arzneimitteln auf die Haut |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| JPH0827003A (ja) * | 1994-07-22 | 1996-01-30 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
| DE4429667C2 (de) * | 1994-08-20 | 1996-07-11 | Lohmann Therapie Syst Lts | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
| DE4429664C2 (de) * | 1994-08-20 | 1997-09-11 | Lohmann Therapie Syst Lts | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
| DE19548332A1 (de) * | 1995-12-22 | 1997-07-10 | Rotta Res Bv | Hormonpflaster |
| DE19600347A1 (de) * | 1996-01-08 | 1997-07-10 | Lohmann Therapie Syst Lts | Hauthaftende pharmazeutische Zubereitung, insbesondere TTS zur Abgabe von 17-beta-Estradiol an den menschlichen Organismus |
-
1998
- 1998-06-22 DE DE19827732A patent/DE19827732A1/de not_active Ceased
-
1999
- 1999-06-22 PL PL99345061A patent/PL345061A1/xx unknown
- 1999-06-22 PT PT99931130T patent/PT1089722E/pt unknown
- 1999-06-22 DK DK99931130T patent/DK1089722T3/da active
- 1999-06-22 DE DE69901561T patent/DE69901561T2/de not_active Expired - Fee Related
- 1999-06-22 IL IL14033599A patent/IL140335A0/xx unknown
- 1999-06-22 CA CA002333586A patent/CA2333586A1/en not_active Abandoned
- 1999-06-22 HU HU0102785A patent/HUP0102785A2/hu unknown
- 1999-06-22 KR KR1020007014543A patent/KR20010053072A/ko not_active Withdrawn
- 1999-06-22 EP EP99931130A patent/EP1089722B1/en not_active Expired - Lifetime
- 1999-06-22 US US09/720,324 patent/US6440454B1/en not_active Expired - Fee Related
- 1999-06-22 BR BR9911411-9A patent/BR9911411A/pt not_active Application Discontinuation
- 1999-06-22 ES ES99931130T patent/ES2177295T3/es not_active Expired - Lifetime
- 1999-06-22 WO PCT/EP1999/004305 patent/WO1999066908A1/en not_active Ceased
- 1999-06-22 JP JP2000555594A patent/JP2002518434A/ja active Pending
- 1999-06-22 CN CN99807718A patent/CN1306421A/zh active Pending
- 1999-06-22 AT AT99931130T patent/ATE217793T1/de not_active IP Right Cessation
- 1999-06-22 AU AU47754/99A patent/AU4775499A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL140335A0 (en) | 2002-02-10 |
| US6440454B1 (en) | 2002-08-27 |
| EP1089722B1 (en) | 2002-05-22 |
| DE69901561T2 (de) | 2002-10-10 |
| BR9911411A (pt) | 2001-10-23 |
| PL345061A1 (en) | 2001-11-19 |
| CA2333586A1 (en) | 1999-12-29 |
| DE19827732A1 (de) | 1999-12-23 |
| PT1089722E (pt) | 2002-09-30 |
| AU4775499A (en) | 2000-01-10 |
| ATE217793T1 (de) | 2002-06-15 |
| KR20010053072A (ko) | 2001-06-25 |
| EP1089722A1 (en) | 2001-04-11 |
| WO1999066908A1 (en) | 1999-12-29 |
| CN1306421A (zh) | 2001-08-01 |
| JP2002518434A (ja) | 2002-06-25 |
| DE69901561D1 (de) | 2002-06-27 |
| DK1089722T3 (da) | 2002-07-01 |
| HUP0102785A2 (hu) | 2002-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1089722E (pt) | Penso transdermico do tipo de matriz para hormonas esteroides | |
| AR010301A1 (es) | Emulsion de pantalla solar | |
| ES2129980T3 (es) | Sistema de afeitado en humedo con un material compuesto que favorece el afeitado, con un complejo de inclusion de un agente suavizante de la piel y ciclodextrina. | |
| BR0007919A (pt) | Composição purina 2,6,9-trisubstituìda | |
| ES2174517T3 (es) | Composiciones cosmeticas con dibenciliden sorbitol y siliconas funcionalizadas. | |
| ES2158956T3 (es) | Formulacion de cafeina de cesion sostenida. | |
| ATE288744T1 (de) | Arzneiformulierungen zur hormonersatztherapie zur topischen anwendung auf der haut | |
| ES2173978T3 (es) | Utilizacion de un alcohol graso insaturado. | |
| BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
| CO5251434A1 (es) | Composicion de liberacion controlada | |
| BR9815378A (pt) | Sistema de fornecimento de droga transdérmico para agente analgésico antiinflamatório compreendendo sal de dietilamÈnio diclofenac e o método de fabricação do mesmo. | |
| BR0304289A (pt) | Composições e artigos depilatórios e uso dos mesmos | |
| AR004089A1 (es) | Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante. | |
| PE20040068A1 (es) | Decanoato, undecanoato y dodecanoato de etonogestrel | |
| YU14394A (sh) | Flaster sa aktivnom supstancom za davanje estradiola na kožu | |
| MX9703281A (es) | Un sistema de suministro para agentes antimetanogenicos. | |
| KR900007424A (ko) | 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물 | |
| CO5190673A1 (es) | Nueva composicion y uso liberacion modificada | |
| ES2178425T3 (es) | Agente protector contra el sol. | |
| AR043013A1 (es) | Composicion farmaceutica destinada al tratamiento de la endometriosis | |
| YU2594A (sh) | Flaster koji sadrži nitroglicerin i postupak za njegovo dobijanje | |
| AR016350A1 (es) | Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos | |
| AR006477A1 (es) | Una composicion antitranspirante o desodorante para la aplicacion topica a la piel humana | |
| AR011807A1 (es) | Una composicion antitranspirante en aerosol sustancialmente anhidra para la aplicacion topica sobre la piel humana, y uso no terapeutico de dicha composicion. | |
| CR6452A (es) | Composicion de resorcinol |